Private equity has been buying up medical practices for years, but chiropractic care – long considered too fragmented, too cash-pay, and too dependent on individual practitioner reputation – is now squarely in the crossroads of the rollup machine.
Why Chiropractic Is Suddenly Attractive to PE Firms
For most of its history, chiropractic care operated as a cottage industry. A practitioner would build a patient base over a decade, maybe hire one associate, and eventually sell to another individual chiropractor at retirement. The practices were small, the margins were tight, and insurance reimbursements were inconsistent enough to scare off institutional buyers. That calculus has shifted. The combination of growing consumer demand for non-opioid pain management, expanding insurance coverage in many states, and the sheer volume of solo and two-person practices has made chiropractic an appealing consolidation target.
The math behind a rollup strategy in chiropractic is straightforward. A solo practice might sell at a modest multiple of earnings – often in the range of three to five times EBITDA – because individual buyers lack negotiating leverage and operational sophistication. A PE-backed platform that assembles fifty of those practices can renegotiate insurance contracts at scale, centralize billing and administrative functions, and then sell the entire group at a far higher multiple to a larger buyer or take it public. The spread between the acquisition price and the eventual exit price is where the return gets generated.
Chiropractic also benefits from relatively low overhead compared to surgical specialties. There are no operating rooms to staff, no implant supply chains to manage, and the regulatory environment – while still complex – is less burdensome than acute care. That lowers the barrier to rapid geographic expansion, which is what rollup strategies depend on. A PE firm can move faster in chiropractic than it can in, say, cardiology or orthopedic surgery, where credentialing, hospital privileges, and equipment costs slow the pace considerably.
The patient volume dynamic matters too. Chiropractic patients tend to return regularly – weekly or biweekly visits are common for chronic pain management – which creates recurring revenue that is appealing from a financial modeling perspective. Subscription-style wellness plans, which some chiropractic groups have started selling, amplify that predictability further. For a PE firm building a platform company, recurring revenue is essentially the holy grail.
What Selling Practitioners Actually Experience
The pitch that PE-backed acquirers bring to chiropractic owners typically arrives with a mix of financial relief and professional reassurance. Owners are told they will retain clinical autonomy, continue seeing their own patients, and receive a meaningful upfront payment – often the largest single check they have ever seen. For a practitioner who has spent fifteen years building a practice and is staring down burnout, that offer can be genuinely difficult to decline. The paperwork gets signed, and for a period of six to twelve months, not much changes visibly.
The friction tends to arrive later. Centralized billing systems may prioritize insurance-covered visits over the cash-pay wellness services that many chiropractors built their practices around. Scheduling software gets standardized, which can mean shorter appointment windows and higher daily patient quotas. Staff who were hired by the original owner and are loyal to that owner may find themselves reporting to regional managers they have never met. The culture of a practice – which in chiropractic is often the entire product – is not easy to preserve inside a corporate structure optimizing for throughput.
Some practitioners have found ways to negotiate better terms, particularly around non-compete agreements, which in chiropractic rollups can be aggressively broad. A chiropractor who signs a five-year non-compete covering a twenty-mile radius is essentially betting that the new ownership will keep them satisfied, because leaving to start fresh nearby becomes legally complicated. The attorneys representing PE buyers draft these agreements with that constraint in mind. Sellers who bring their own legal counsel – which many solo practitioners do not bother to do – tend to fare meaningfully better in the final terms.
There is also the question of what happens to the patient relationship. Long-term chiropractic patients often have a deeply personal connection to their provider. When a practice sells to a rollup, that provider may eventually leave anyway – either voluntarily or because the new employment terms become untenable – and the patient is left with a corporate entity rather than the practitioner they chose. Some rollup platforms have addressed this by prioritizing provider retention aggressively in their first year post-acquisition, understanding that the value they bought is essentially goodwill that walks out the door if the doctors leave.
This pattern is not unique to chiropractic. The same dynamic played out in ophthalmology, where regional ophthalmology practices selling to PE rollups faced similar questions about clinical autonomy and patient continuity once the acquisition closed. The structural pressures are nearly identical – fragmented ownership, aging practitioner base, and a reimbursement environment that rewards scale.
Where the Rollup Wave Goes From Here
The chiropractic rollup market is still in early innings compared to where dentistry or dermatology were a decade ago, when PE consolidation was already well advanced. That means there is still a large pool of independent practices that have not been approached, and that PE firms building platforms are actively competing with each other to acquire them first. The pace of deal activity has accelerated in the past two years, and owners in mid-sized markets who might have assumed they were too small to attract institutional interest are increasingly finding that assumption wrong.
The more interesting question is what happens when the first wave of chiropractic platforms reaches exit. The buyers at that stage – strategic acquirers, larger PE funds, or public market investors – will be scrutinizing patient retention rates, provider turnover, and same-store revenue growth. If the platforms that rushed to scale did so by squeezing practices hard, those metrics will reflect it. The exit multiples that made the rollup arithmetic so attractive on paper depend entirely on the acquirer believing the revenue is durable – and in a care model built on personal relationships, that durability is never guaranteed.
